Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Daylight-mediated Photodynamic Therapy of Actinic Keratoses: a Randomized, Double-blinded Pilot Study Comparing Topical 0.2% Hexylaminolaevulinate With 16% Methylaminolaevulinate

Next Previous
Trial Profile

Daylight-mediated Photodynamic Therapy of Actinic Keratoses: a Randomized, Double-blinded Pilot Study Comparing Topical 0.2% Hexylaminolaevulinate With 16% Methylaminolaevulinate

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hexyl aminolevulinate (Primary) ; Methyl aminolevulinate
  • Indications Actinic keratosis
  • Focus Therapeutic Use

Most Recent Events

  • 29 May 2016 Status changed from recruiting to completed.
  • 04 Dec 2014 Drug concentration in the experimental treatment arm (hexyl-aminolevulinate) has been changed from 2% to 0.2% and 2% as reported by ClinicalTrials.gov record.
  • 04 Dec 2014 Planned End Date changed from 1 Dec 2015 to 1 May 2016 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top